ALL ) with the Abl-tyrosine kinase inhibitor STI 571 ( Glivec ) + leukemia ( Ph Philadelphia chromosome / Bcr-Bbl positive acute lymphoblastic Early minimal residual disease ( MRD ) analysis during treatment
暂无分享,去创建一个
H. Gschaidmeier | O. Ottmann | B. Wassmann | D. Hoelzer | H. Pfeifer | U. Scheuring | P. Brueck | B. Gehrke | Eduard K Johannes Atta
[1] Sante Tura,et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.
[2] D. Hoelzer,et al. Recent approaches in acute lymphoblastic leukemia in adults. , 2002, Critical reviews in oncology/hematology.
[3] S. de Vos,et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. , 2002, Blood.
[4] T. Lipp,et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. , 2002, Blood.
[5] David Elashoff,et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study , 2002, The Lancet.
[6] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[7] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[8] H. Mano,et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. , 2001, Blood.
[9] J. Topaly,et al. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells , 2001, Leukemia.
[10] N. Goulden,et al. Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia , 2001, British journal of haematology.
[11] J. Radich. Philadelphia chromosome-positive acute lymphocytic leukemia. , 2001, Hematology/oncology clinics of North America.
[12] Z. Estrov,et al. Studies of minimal residual disease in acute lymphocytic leukemia. , 2000, Hematology/oncology clinics of North America.
[13] T. Lipp,et al. Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). , 2000, Hematology/oncology clinics of North America.
[14] K. Kolibaba,et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. , 2000, Blood.
[15] E. Macintyre,et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.
[16] U. Jaeger,et al. Quantification of minimal residual disease in patients with BCR‐ABL‐positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction , 1999, British journal of haematology.
[17] George Q. Daley,et al. The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity , 1999, The Journal of experimental medicine.
[18] L. Foroni,et al. INVESTIGATION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA BY MOLECULAR ANALYSIS , 1999, British journal of haematology.
[19] J. Hancock,et al. Minimal Residual Disease Status Before Allogeneic Bone Marrow Transplantation Is an Important Determinant of Successful Outcome for Children and Adolescents With Acute Lymphoblastic Leukemia , 1998 .
[20] W. Hop,et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.
[21] H. Cavé,et al. Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .
[22] J. Hancock,et al. Minimal residula disease status as a predictor of relapse after allogenic bone marrow transplantation for children with acute lymphoblastic leukaemia , 1998, British journal of haematology.
[23] A. Morley,et al. Monitoring minimal residual disease in peripheral blood in B‐lineage acute lymphoblastic leukaemia , 1997, British journal of haematology.
[24] L. Foroni,et al. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response , 1997, Leukemia.
[25] P. Sykes,et al. Effect of the Philadelphia chromosome on minimal residual disease in acute lymphoblastic leukemia , 1997, Leukemia.
[26] J. Radich,et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. , 1997, Blood.
[27] C. Preudhomme,et al. Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL) , 1997, Leukemia.
[28] A. Morley,et al. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. , 1996, Blood.
[29] J. Goldman,et al. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. , 1995, Leukemia.
[30] A. Morley,et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction , 1994, The Lancet.
[31] K. Sikora,et al. Leukemia , 1984, British Journal of Cancer.
[32] R. Larson,et al. Acute Lymphocytic Leukemia in Adults , 2000 .
[33] J. V. van Dongen,et al. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. , 1992, Leukemia.